Enhanced stem cell composition
AssigneeFate Therapeutics, Inc.
InventorsDan Shoemaker, David Robbins, John D. Mendlein, Caroline Desponts
Life of this patent
Estimating the term…
Abstract
The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
Claims162
A human hematopoietic stem or progenitor cell comprising:
- a) a hematopoietic stem or progenitor cell that has been contacted ex vivo with one or more agents that increase CXCR4 gene expression in the cells;
- and
- b) gene expression of CXCR4 is increased at least about 30 fold in the contacted hematopoietic stem or progenitor cell compared to non-contacted hematopoietic stem or progenitor cells.
A therapeutic composition comprising a population of cells comprising human hematopoietic stem or progenitor cells wherein:
- a) the hematopoietic stem or progenitor cells have been contacted ex vivo with one or more agents that increase CXCR4 expression in the human hematopoietic stem or progenitor cells;
- and
- b) gene expression of CXCR4 is increased at least about 30 fold in the contacted hematopoietic stem or progenitor cells compared to non-contacted hematopoietic stem or progenitor cells.
A method of preparing a human hematopoietic stem or progenitor cell comprising
- a) contacting the hematopoietic stem or progenitor cell ex vivo with one or more agents that increase CXCR4 gene expression in the cells;
- wherein the CXCR4 gene expression is increased at least about 30 fold in the contacted hematopoietic stem or progenitor cell compared to non-contacted hematopoietic stem or progenitor cells.
A method of preparing a therapeutic composition comprising:
- contacting hematopoietic stem or progenitor cells ex vivo with (i) one or more prostaglandin pathway agonists and (ii) one or more glucocorticoids;
- wherein the CXCR4 gene expression is increased at least about 30 fold in the contacted hematopoietic stem or progenitor cells compared to non-contacted hematopoietic stem or progenitor cells.
A method of increasing hematopoietic stem and progenitor cell homing and/or engraftment in a subject comprising administering to the subject a composition comprising a population of cells comprising human hematopoietic stem or progenitor cells wherein:
- a) the hematopoietic stem or progenitor cells have been contacted ex vivo with one or more agents that increase CXCR4 gene expression in the cells;
- and
- b) gene expression of CXCR4 is increased at least about 30 fold in the contacted hematopoietic stem or progenitor cells compared to non-contacted hematopoietic stem or progenitor cells.
A method of increasing hematopoietic stem and progenitor cell homing and/or engraftment in a subject comprising administering to the subject a composition comprising a population of cells comprising human hematopoietic stem or progenitor cells wherein:
- a) the hematopoietic stem or progenitor cells have been contacted ex vivo with (i) one or more prostaglandin pathway agonists and (ii) one or more glucocorticoids;
- and
- b) gene expression of CXCR4 is increased at least about 30 fold in the contacted hematopoietic stem or progenitor cells compared to non-contacted hematopoietic stem or progenitor cells.
A method of increasing hematopoietic stem and progenitor cell reconstitution in a subject comprising administering to the subject a composition comprising a population of cells comprising human hematopoietic stem or progenitor cells wherein:
- a) the hematopoietic stem or progenitor cell has been contacted ex vivo with one or more agents that increase CXCR4 gene expression in the cells;
- and
- b) gene expression of CXCR4 is increased at least about 30 fold in the contacted hematopoietic stem or progenitor cell compared to non-contacted hematopoietic stem or progenitor cells.
A method of increasing hematopoietic stem and progenitor cell reconstitution in a subject comprising administering to the subject a composition comprising a population of cells comprising human hematopoietic stem or progenitor cells wherein:
- a) the hematopoietic stem or progenitor cells have been contacted ex vivo with (i) one or more prostaglandin pathway agonists and (ii) one or more glucocorticoids;
- and
- b) gene expression of CXCR4 is increased at least about 30 fold in the contacted hematopoietic stem or progenitor cells compared to non-contacted hematopoietic stem or progenitor cells.
Dependencies are inferred from the claim text.